Multi-epitope based vaccine against yellow fever virus applying immunoinformatics approaches

Tosta, Stephane; Passos, Mariana Santana; Kato, Rodrigo Bentes; Salgado, Álvaro; Xavier, Joilson; Jaiswal, Arun Kumar; Soares, Siomar C.; Azevedo, Vasco; Giovanetti, Marta; Tiwari, Sandeep; Alcântara, Luíz Carlos Júnior

doi:10.1080/07391102.2019.1707120

Cited by 40 publications

(31 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Henceforth, in the current approach, we have checked the propensity of the multi-epitope vaccine construct of the Nipah virus and human TLR3 complex. This epitope-based vaccine development approach has been explored and proved to be promising in a number of diseases caused by viruses like Herpes simplex virus (Hasan et al, 2019;Kumar et al, 2019), Yellow Fever Virus (Tosta et al, 2019), SARS Coronavirus (Srivastava et al, 2019), Chikungunya (Bappy et al, 2020), Dengue (Sabetian, Nezafat, Dorosti, Zarei, & Ghasemi, 2019), Alkhurma hemorrhagic fever virus (Ul-Rahman & Shabbir, 2019), etc. as well as by other pathogens including Leishmania donovani (Khatoon et al, 2019), Elizabethkingia anophelis (Nain et al, 2019), Flavobacterium columnare (Bhattacharya et al, 2020), Bacillus anthracis (Gupta, Khatoon, Mishra, Verma, & Prajapati, 2019), Streptococcus pneumoniae (Dorosti et al, 2019), Helicobacter pylori (Pasala et al, 2019), etc.…”

Section: Introductionmentioning

confidence: 99%

Designing of a multi-epitope vaccine candidate against Nipah virus by in silico approach: a putative prophylactic solution for the deadly virus

Majee

Jain

Kumar

2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

Nipah virus (NPV) is one of the most notorious viruses with a very high fatality rate. Because of the recurrent advent of this virus and its severe neurological implications, often leading to high mortality, the WHO R&D Blueprint, 2018 has listed the Nipah virus as one of the emerging infectious diseases requiring urgent research and development effort. Yet there is a major layback in the development of effective vaccines or drugs against NPV. In this study, we have designed a stable multivalent vaccine combining several T-cell and B-cell epitopes of the essential Nipah viral proteins with the help of different ligands and adjuvants which can effectively induce both humoral and cellular immune responses in human. Different advanced immune-informatic tools confirm the stability, high immunogenicity and least allergenicity of the vaccine candidate. The standard molecular dynamic cascade analysis validates the stable interaction of the vaccine construct with the human Toll-like receptor 3 (TLR3) complex. Later, codon optimization and in silico cloning in a known pET28a vector system shows the possibility for the expression of this vaccine in a simple organism like E.coli. It is believed that with further in vitro and in vivo validation, this vaccine construct can pose to be a better prophylactic solution to the Nipah viral disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Designing of a multi-epitope vaccine candidate against Nipah virus by in silico approach: a putative prophylactic solution for the deadly virus

Majee

Jain

Kumar

2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

show abstract

“…The announcement of emergency by the World Health Organization (WHO) on the COVID-19 outbreak urged researchers to develop therapeutics, mainly the identification of drug candidates or vaccines [20]. The use of cost-effective and less time-consuming methods, especially immunoinformatics approaches, haas already assisted the researchers to predict potential antigenic epitopes for the multiepitope-based vaccine [38][39][40]44,75,[100][101][102]. The multiple epitope vaccine has a distinctive design concept compared with classical single-epitope based vaccines [101,[103][104][105].…”

Section: Discussionmentioning

confidence: 99%

“…Various limitations are there in the context of appropriate candidate antigens, their immunodominant epitopes, and experimental methods, which include the development of an effective delivery system [108,109]. Investigation of the whole spectrum of probable antigens is achievable through immunoinformatics and with the aid of molecular modelling to analyze the potential binding with host proteins [30,32,38,41,109]. Besides, the difficulty of culturing the pathogens as well as in vitro antigen expression problems can be avoided [102,110].…”

Section: Discussionmentioning

confidence: 99%

“…The current study deals with the modelling of novel multiepitope vaccine for SARS-CoV-2 using a cost-effective integrated immunoinformatics approach. This approach has been proved to be promising against viral diseases caused by viruses like yellow fever [38], SARS-CoV [39], influenza [40], Zika [41], Congo Virus [42], and pathogens including L. donovani [43] and S. pneumoniae [44]. Few multiple epitope vaccine strategies proved to be effective against H. pylori infection in the BALB/c mice model [45,46], chronic hepatitis B virus infection [47], and foot-and-mouth disease virus (serotype A) in pigs [48].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Putative Prophylactic Solution for COVID-19: Development of Novel Multiepitope Vaccine Candidate against SARS-COV-2 by Comprehensive Immunoinformatic and Molecular Modelling Approach

Rehman

Mirza

Ahmad

et al. 2020

Biology

View full text Add to dashboard Cite

The outbreak of 2019-novel coronavirus (SARS-CoV-2) that causes severe respiratory infection (COVID-19) has spread in China, and the World Health Organization has declared it a pandemic. However, no approved drug or vaccines are available, and treatment is mainly supportive and through a few repurposed drugs. The urgency of the situation requires the development of SARS-CoV-2-based vaccines. Immunoinformatic and molecular modelling are time-efficient methods that are generally used to accelerate the discovery and design of the candidate peptides for vaccine development. In recent years, the use of multiepitope vaccines has proved to be a promising immunization strategy against viruses and pathogens, thus inducing more comprehensive protective immunity. The current study demonstrated a comprehensive in silico strategy to design stable multiepitope vaccine construct (MVC) from B-cell and T-cell epitopes of essential SARS-CoV-2 proteins with the help of adjuvants and linkers. The integrated molecular dynamics simulations analysis revealed the stability of MVC and its interaction with human Toll-like receptors (TLRs), which trigger an innate and adaptive immune response. Later, the in silico cloning in a known pET28a vector system also estimated the possibility of MVC expression in Escherichia coli. Despite that this study lacks validation of this vaccine construct in terms of its efficacy, the current integrated strategy encompasses the initial multiple epitope vaccine design concepts. After validation, this MVC can be present as a better prophylactic solution against COVID-19.

show abstract

“…TLR-2 and TLR-4 are involved in recognition of viral structural proteins followed by production of cytokines and even in SARS CoV, they have been found to induce effective immune responses. Certain studies on SARS CoV and MERS CoV even indicated the noteworthy role of TLR 3 in generating protective responses against the virus [9][10][11][12][13][14] . So, the vaccine was docked with the immunological receptors: TLR-2, TLR-3 and TLR-4.…”

Section: Introductionmentioning

confidence: 99%

Immuno-informatics approach for multi-epitope vaccine designing against SARS-CoV-2

Banerjee

Majumder

Gutierrez

et al. 2020

Preprint

View full text Add to dashboard Cite

The novel Corona Virus Disease (COVID-19) pandemic has spread a blaze of increasing fatality rates across the world. The dearth of potential vaccines has left the survival of mankind with doubts. The development of multi-epitope vaccine in this current situation could be a possible COVID treatment. We have designed a novel multi-epitope, multi-protein vaccine with different proteins of Severe Acute Respiratory Syndrome - Corona Virus -2 (SARS-CoV-2) with immuno-informatics approaches, which has been validated in silico to be stable and potential. It has been prepared with Cytotoxic T-cell (TC) and Helper T-cell (TH) binding epitopes overlapping with B-cell binding epitopes predicted for 6 proteins conserved among 4 different viral strains isolated across the world. Both the humoral and cell-mediated immune responses are ensured due to the presence of T cell and B-cell inducing epitopes along with interferon-gamma inducing epitopes present in the vaccine. The final vaccine construct comprises of an adjuvant at the N terminal, Cytotoxic T Lymphocyte and Helper T Lymphocyte epitopes. The construct showed potential antigenicity and was non-allergic. The molecular docking of the refined, validated tertiary structure model of the vaccine was performed with immune-stimulatory Toll Like Receptors (TLR), TLR-2,3,4. The study of binding energetics of the docked complexes revealed binding interactions of receptor with vaccine. The immune simulation of the vaccine even confirmed the initiation of elevated host immune responses. The efficient translation of the vaccine in an expression vector was confirmed with in silico cloning approach. Certainly, the development of such vaccine candidate could possibly be an effective therapy for COVID-19.

show abstract

Multi-epitope based vaccine against yellow fever virus applying immunoinformatics approaches

Cited by 40 publications

References 108 publications

Designing of a multi-epitope vaccine candidate against Nipah virus by in silico approach: a putative prophylactic solution for the deadly virus

Designing of a multi-epitope vaccine candidate against Nipah virus by in silico approach: a putative prophylactic solution for the deadly virus

A Putative Prophylactic Solution for COVID-19: Development of Novel Multiepitope Vaccine Candidate against SARS-COV-2 by Comprehensive Immunoinformatic and Molecular Modelling Approach

Immuno-informatics approach for multi-epitope vaccine designing against SARS-CoV-2

Contact Info

Product

Resources

About